Sentiment-Signal
12,6
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (25.02.2026)
HOCH Abgang Schlüsselpersonen (25.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 25.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | xhibit 99.1.* Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Office |
| 21.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 02.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 21.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 26.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 02.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 28.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 02.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
| 10.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensato |
Stammdaten
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Unternehmen & Branche
| Name | ADMA BIOLOGICS, INC. |
|---|---|
| Ticker | ADMA |
| CIK | 0001368514 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,45 Mrd. USD |
| Beta | 0,82 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 510,173,000 | 146,930,000 | 0.60 | 624,242,000 | 477,320,000 |
| 2025-09-30 | 10-Q | 134,224,000 | 36,428,000 | 0.15 | 568,687,000 | 431,186,000 |
| 2025-06-30 | 10-Q | 121,984,000 | 34,219,000 | 0.14 | 558,380,000 | 398,325,000 |
| 2025-03-31 | 10-Q | 114,802,000 | 26,904,000 | 0.11 | 510,569,000 | 373,419,000 |
| 2024-12-31 | 10-K | 426,454,000 | 197,673,000 | 0.81 | 488,678,000 | 349,018,000 |
| 2024-09-30 | 10-Q | 119,839,000 | 35,909,000 | 0.15 | 390,618,000 | 231,890,000 |
| 2024-06-30 | 10-Q | 107,191,000 | 32,062,000 | 0.13 | 376,399,000 | 188,269,000 |
| 2024-03-31 | 10-Q | 81,875,000 | 17,806,000 | 0.08 | 350,875,000 | 153,706,000 |
| 2023-12-31 | 10-K | 258,215,000 | -28,239,000 | -0.13 | 329,182,000 | 135,206,000 |
| 2023-09-30 | 10-Q | 67,275,000 | 2,565,000 | 0.01 | 348,997,000 | 151,437,000 |
| 2023-06-30 | 10-Q | 60,123,000 | -6,371,000 | -0.03 | 343,027,000 | 146,762,000 |
| 2023-03-31 | 10-Q | 56,914,000 | -6,789,000 | -0.03 | 340,788,000 | 145,655,000 |
| 2022-12-31 | 10-K | 154,080,000 | -65,904,000 | -0.33 | 348,461,000 | 151,974,000 |
| 2022-09-30 | 10-Q | 41,090,137 | -14,899,504 | -0.08 | 300,557,570 | 100,384,536 |
| 2022-06-30 | 10-Q | 33,905,007 | -13,764,906 | -0.07 | 296,932,329 | 114,400,527 |
| 2022-03-31 | 10-Q | 29,103,093 | -25,007,857 | -0.13 | 308,032,492 | 126,933,065 |
| 2021-12-31 | 10-K | 80,943,000 | -71,648,000 | -0.51 | 276,253,000 | 141,173,000 |
| 2021-09-30 | 10-Q | 20,680,550 | -17,712,954 | -0.13 | 238,640,406 | 102,780,167 |
| 2021-06-30 | 10-Q | 17,830,590 | -18,905,303 | -0.15 | 232,813,792 | 111,593,532 |
| 2021-03-31 | 10-Q | 16,048,618 | -18,379,941 | -0.16 | 235,667,028 | 112,504,086 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 15.16 | -90,960.00 | -19,9% | |
| 2026-03-16 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 15.16 | -227,400.00 | -49,8% | |
| 2026-03-09 | Kestenberg-Messina Kaitlin M. | Officer, COO and SVP, Compliance | Open Market Sale | -10,096 | 15.63 | -157,800.48 | -34,6% | |
| 2026-03-06 | ELMS STEVE | Director | Open Market Purchase | 7,000 | 15.39 | 107,730.00 | +23,6% | |
| 2026-03-05 | ELMS STEVE | Director | Open Market Purchase | 7,000 | 15.67 | 109,690.00 | +24,0% | |
| 2026-02-17 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 16.08 | -96,480.00 | -21,1% | |
| 2026-02-17 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 16.08 | -241,200.00 | -52,8% | |
| 2025-12-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 19.79 | -296,850.00 | -65,0% | |
| 2025-12-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 19.79 | -118,740.00 | -26,0% | |
| 2025-11-19 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 16.00 | -240,000.00 | -52,6% | |
| 2025-11-19 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 16.00 | -96,000.00 | -21,0% | |
| 2025-10-24 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 16.00 | -240,000.00 | -52,6% | |
| 2025-10-24 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 16.00 | -96,000.00 | -21,0% | |
| 2025-09-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 16.13 | -96,780.00 | -21,2% | |
| 2025-09-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 16.13 | -241,950.00 | -53,0% | |
| 2025-08-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 16.88 | -253,200.00 | -55,5% | |
| 2025-08-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 16.88 | -101,280.00 | -22,2% | |
| 2025-07-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 18.66 | -111,960.00 | -24,5% | |
| 2025-07-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 18.66 | -279,900.00 | -61,3% | |
| 2025-06-16 | ELMS STEVE | Director | Open Market Sale | -194,749 | 20.24 | -3,941,719.76 | -863,6% | |
| 2025-06-16 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 20.81 | -312,150.00 | -68,4% | |
| 2025-06-16 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 20.81 | -124,860.00 | -27,4% | |
| 2025-06-13 | ELMS STEVE | Director | Open Market Sale | -137,931 | 20.82 | -2,871,723.42 | -629,1% | |
| 2025-06-12 | ELMS STEVE | Director | Open Market Sale | -92,941 | 21.69 | -2,015,890.29 | -441,6% | |
| 2025-06-09 | Guiheen Lawrence P. | Director | Open Market Sale | -20,000 | 20.96 | -419,200.00 | -91,8% | |
| 2025-06-09 | Grossman Jerrold B | Director | Open Market Sale | -10,000 | 21.31 | -213,100.00 | -46,7% | |
| 2025-05-22 | Guiheen Lawrence P. | Director | Open Market Sale | -1,221 | 20.12 | -24,566.52 | -5,4% | |
| 2025-05-21 | Guiheen Lawrence P. | Director | Open Market Sale | -7,779 | 20.32 | -158,069.28 | -34,6% | |
| 2025-05-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -15,000 | 19.45 | -291,750.00 | -63,9% | |
| 2025-05-15 | Grossman Adam S | Director, Officer, President and CEO | Open Market Sale | -6,000 | 19.45 | -116,700.00 | -25,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.